VIR-5500

Asset

Dual-masked T-cell engager targeting PSMA and CD3 to direct T cells to prostate cancer cells

Stage
Phase 1
Modality
Antibody
Target
CD3E
1
Indication
0
Trials
1
Developer

Indications

1
  • Metastatic castration-resistant prostate cancer

    Phase 1, businesswire.com, 8 Oct 2026

In the full profile

  • Targets and what it contains2
  • Owner and partners2
  • Evidence for its targets2
  • Competitors4
  • Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets